REGENT PACIFIC (00575.HK): Accrua Health Launch Revised to Q4
NewTimeSpace News: On 30 October 2026, Regent Pacific Group Limited (stock code: 00575) voluntarily announced a revised launch timetable for Accrua Health (formerly Accrua), Deep Longevity's consumer digital health and telemedicine platform in the US, which is now expected to launch in the fourth quarter of 2026.
The announcement stated that the launch will proceed in phases: an invitation-only pilot in Q4, followed by a public waiting list stage, and ultimately a full commercial launch. The brief delay reflects the time needed to onboard Deep Longevity's telemedicine infrastructure partner and digital advertising agency, and to integrate the BloodAge report into a partner's electronic health record (EHR) platform.
The company said Accrua Health's first phase covers medical weight loss, longevity and anti-aging peptide treatments, the second adds testosterone and hormone replacement therapy, and the third introduces more programmes, all centred on Deep Longevity's proprietary AI-generated BloodAge report. The company expects these developments to have no material impact on its financial position or results for the financial year ending 31 December 2026.
- REGENT PACIFIC (00575.HK): Accrua Platform to Launch in US in October
- REGENT PACIFIC (00575.HK): Net milestone payment of USD 4.5 million received from Fosun Wanbang, further value expected from Senstend commercialization in China
- REGENT PACIFIC(00575.HK): Deep Longevity Blood Biological Age Model Proven to Predict Mortality and Hospitalisation Risks in Research
- REGENT PACIFIC(00575.HK): Wholly-owned Subsidiary Deep Longevity Named Runner-up in Nestlé VITAL Smart Aging Global Challenge
- REGENT PACIFIC(00575.HK) closed 78.95% higher on Jun 17, leading the Hang Seng Pharmaceuticals & Biotechnology Sector
